Imagion Biosystems has lodged the announcement “Despatch of Rights Issue Offer Documents” with the Australian Securities Exchange.
View Despatch of Rights Issue Offer Documents.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance